- Home
- PCTY vs EXEL Comparison
PCTY vs EXEL Comparison
Compare PCTY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCTY
- EXEL
- Stock Information
- Founded
- PCTY 1997
- EXEL 1994
- Country
- PCTY United States
- EXEL United States
- Employees
- PCTY N/A
- EXEL N/A
- Industry
- PCTY Computer Software: Prepackaged Software
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCTY Technology
- EXEL Health Care
- Exchange
- PCTY Nasdaq
- EXEL Nasdaq
- Market Cap
- PCTY 11.7B
- EXEL 9.4B
- IPO Year
- PCTY 2014
- EXEL 2000
- Fundamental
- Price
- PCTY $186.33
- EXEL $36.70
- Analyst Decision
- PCTY Strong Buy
- EXEL Buy
- Analyst Count
- PCTY 17
- EXEL 18
- Target Price
- PCTY $232.65
- EXEL $37.59
- AVG Volume (30 Days)
- PCTY 387.8K
- EXEL 2.7M
- Earning Date
- PCTY 05-01-2025
- EXEL 04-29-2025
- Dividend Yield
- PCTY N/A
- EXEL N/A
- EPS Growth
- PCTY 31.57
- EXEL 170.77
- EPS
- PCTY 3.89
- EXEL 1.76
- Revenue
- PCTY $1,498,504,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- PCTY $13.80
- EXEL $5.45
- Revenue Next Year
- PCTY $10.46
- EXEL $10.32
- P/E Ratio
- PCTY $48.17
- EXEL $20.81
- Revenue Growth
- PCTY 15.96
- EXEL 18.50
- 52 Week Low
- PCTY $129.94
- EXEL $20.14
- 52 Week High
- PCTY $223.80
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- PCTY 38.41
- EXEL 48.90
- Support Level
- PCTY $186.60
- EXEL $36.71
- Resistance Level
- PCTY $198.43
- EXEL $38.41
- Average True Range (ATR)
- PCTY 5.49
- EXEL 1.10
- MACD
- PCTY 0.37
- EXEL -0.18
- Stochastic Oscillator
- PCTY 31.80
- EXEL 21.43
About PCTY Paylocity Holding Corporation
Paylocity is a provider of payroll and human capital management, or HCM, solutions servicing small- to midsize clients in the United States. The company was founded in 1997 and targets businesses with 10 to 5,000 employees and services about 39,000 clients as of fiscal 2024. Alongside core payroll services, Paylocity offers HCM solutions such as time and attendance and recruiting software, as well workplace collaboration and communication tools.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.